

## **MOHSEN (MO) SHAHINPOOR**

Cellular: (505) 975 0888  
Home: (505) 821 3096  
Work: (505) 277 3966, (505) 265 4479

9910 Tanoan Drive, NE  
Albuquerque, NM 87111  
[shah@unm.edu](mailto:shah@unm.edu)

---

6/30/2004

Mr. Kevin E. Weddington, Examiner  
Art Unit 1614  
US Patent and Trademark Office  
Washington, DC 20231

Re: Application No. 10/064,627

Dear Mr. Weddington,


Thank you very much for your office action and your guidance regarding corrections to the claims. According to your advice I have revised claim 1 to meet the 35 U.S.C. 121 requirements to elect a single disclosed species. As you educated me, if this claim is specific then claims 2 as well as 15-23 will be in order because they are dependent on claim 1. The revised claim 1 is stated below:

- 1- Method for lowering ocular hypertension, comprising administering to a patient in need thereof, a topical ophthalmic eye drop or ointment containing Nitric Oxide (NO) releasing agents such as Pyrimidine (also known as Minoxidil or Rogain<sup>RTM</sup>) and cGMP-PDE5 inhibitors such as Sildenafil Citrate (also known as Viagra<sup>RTM</sup>).

I sincerely hope the claims are now satisfactory.

With best personal regards, I remain,

Sincerely,

  
Mohsen Shahinpoor

RECEIVED  
MAY 9 2004  
UNIVERSITY CENTER

